['proliferative diabetic retinopathy']
['emixustat hydrochloride']

        Inclusion Criteria:

          -  Able and willing to provide written informed consent

          -  Documented diagnosis of type 1 or type 2 diabetes mellitus

          -  Meets specific ocular criteria for the study eye including but not limited to, the
             presence of PDR with or without diabetic macular edema in study eye for which
             treatment can be deferred for at least 4 weeks after Day 1 visit

          -  Media clarity, pupillary dilation, and subject cooperation sufficient to obtain
             adequate assessments

        Exclusion Criteria:

          -  Any condition that would preclude participation in the study (e.g., unstable medical
             status including blood pressure, cardiovascular disease or glycemic control)

          -  History of myocardial infarction or other acute cardiac event

          -  History of chronic renal failure requiring dialysis or kidney transplant

          -  Prior participation in any clinical study of emixustat

          -  Treatment with any investigational study drug within 30 days of screening

          -  Known allergy to fluorescein sodium for injection in angiography

          -  Treatment with specific prohibited medications or therapy beginning 4 weeks prior to
             screening and throughout the duration of the study

          -  History of systemic anti-VEGF or pro-VEGF treatment within 4 months prior to
             randomization

          -  Pre-specified laboratory abnormalities at screening

          -  Specific ocular characteristics in the study eye

          -  Male subjects who are not surgically sterile and are not willing to practice a
             medically accepted method of birth control with their female partner of childbearing
             potential from screening through 30 days following completion of the study

          -  Female subjects of childbearing potential who are not willing to practice a medically
             accepted method of birth control with their non-surgically sterile male sexual partner
             from screening through 30 days following completion of the study

          -  Female subjects who are pregnant or lactating
      